Medimmune Ltd. has prepared and tested lipidated peptide analogues with improved stability acting as dual agonists of glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R). They are reported to be useful for the treatment of obesity, nonalcoholic steatohepatitis (NASH) and type 2 diabetes.
Katholieke Universiteit Leuven and Springworks Therapeutics Inc. have jointly identified tetrahydropyridopyrimidines acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) or WW domain-containing transcription regulator protein 1 (WWTR1; TAZ)/TEAD interaction inhibitors.
A Retune Pharma Inc. patent describes new insulin-like growth factor 1 receptor (IGF-1R; CD221) inhibitors reported to be useful for the treatment of cancer, thyroid-associated ophthalmopathy (Graves ophthalmopathy) and autoimmune disease.
Arvinas Operations Inc. has reported the development of diacylglycerol kinase α (DGK-α; DGKA) inhibitors reported to be useful for the treatment of cancer.
Research at Vanderbilt University has led to the identification of new muscarinic M5 receptor antagonists reported to be useful for the treatment of psychiatric disorders.
Nerio Therapeutics Inc. has patented new tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer, diabetes type 2, obesity and metabolic diseases.
C4x Discovery Holdings plc has prepared and tested mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors. As such, they are reported to be useful for the treatment of cancer, asthma, gout and psoriasis, among others.
RSS